Passage Bio

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Passage Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Wellness, Therapeutics sector. The company focuses on Biotechnology and has secured $18.2B in funding across 48 round(s). With a team of 101-250 employees, Passage Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Passage Bio, raised $154.0M. Discover more about their projects, partnerships, and impact on our platform.